NASDAQ Stocks
· Jun 14, 2025 2:10 PM EDT
Not market news
Jasper Therapeutics Reports Encouraging Results from SPOTLIGHT Phase 1b/2a Study of Briquilimab for Chronic Inducible Urticaria
Jasper Therapeutics reports promising SPOTLIGHT study results for briquilimab in treating chronic inducible urticaria with favorable safety outcomes.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
